

# Global Small Molecule Inhibitors for Cancer Therapy Market Research Report 2023

<https://marketpublishers.com/r/G98861FDC1E3EN.html>

Date: December 2023

Pages: 102

Price: US\$ 2,900.00 (Single User License)

ID: G98861FDC1E3EN

## Abstracts

Small molecule inhibitors that block the actions of protein kinases and the associated signaling pathways can thus have significant impact

According to QYResearch's new survey, global Small Molecule Inhibitors for Cancer Therapy market is projected to reach US\$ 97020 million in 2029, increasing from US\$ 50220 million in 2022, with the CAGR of 9.3% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Small Molecule Inhibitors for Cancer Therapy market research.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

## Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Small Molecule Inhibitors for Cancer Therapy market with multiple angles, which provides sufficient supports to readers' strategy and decision making.

## By Company

Bayer

Eisai

Zelgen

Cipla

Natco Pharma

AstraZeneca

Novartis

Roche

Bristol-Myers Squibb

Pfizer

BEACON Pharma

Jiangxi Shanxiang

Yao Pharma

CSPC

CHIATAI Tianqing

Simcere

### Segment by Type

Sorafenib

Lenvatinib

Regorafenib

Osimertinib

Anlotinib

Alectinib

Other

### Segment by Application

Hospital

Clinic

Other

### By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

The Small Molecule Inhibitors for Cancer Therapy report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)

Chapter 2: Global market size, regional market size. Market Opportunities and Challenges

Chapter 3: Companies' Competition Patterns

Chapter 4: Product Type Analysis

Chapter 5: Product Application Analysis

Chapter 6 to 10: Country Level Value Analysis

Chapter 11: Companies' Outline

Chapter 12: Market Conclusions

Chapter 13: Research Methodology and Data Source

## Contents

### 1 REPORT OVERVIEW

- 1.1 Study Scope
- 1.2 Market Analysis by Type
  - 1.2.1 Global Small Molecule Inhibitors for Cancer Therapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
  - 1.2.2 Sorafenib
  - 1.2.3 Lenvatinib
  - 1.2.4 Regorafenib
  - 1.2.5 Osimertinib
  - 1.2.6 Anlotinib
  - 1.2.7 Alectinib
  - 1.2.8 Other
- 1.3 Market by Application
  - 1.3.1 Global Small Molecule Inhibitors for Cancer Therapy Market Growth by Application: 2018 VS 2022 VS 2029
  - 1.3.2 Hospital
  - 1.3.3 Clinic
  - 1.3.4 Other
- 1.4 Study Objectives
- 1.5 Years Considered
- 1.6 Years Considered

### 2 GLOBAL GROWTH TRENDS

- 2.1 Global Small Molecule Inhibitors for Cancer Therapy Market Perspective (2018-2029)
- 2.2 Small Molecule Inhibitors for Cancer Therapy Growth Trends by Region
  - 2.2.1 Global Small Molecule Inhibitors for Cancer Therapy Market Size by Region: 2018 VS 2022 VS 2029
  - 2.2.2 Small Molecule Inhibitors for Cancer Therapy Historic Market Size by Region (2018-2023)
  - 2.2.3 Small Molecule Inhibitors for Cancer Therapy Forecasted Market Size by Region (2024-2029)
- 2.3 Small Molecule Inhibitors for Cancer Therapy Market Dynamics
  - 2.3.1 Small Molecule Inhibitors for Cancer Therapy Industry Trends
  - 2.3.2 Small Molecule Inhibitors for Cancer Therapy Market Drivers

2.3.3 Small Molecule Inhibitors for Cancer Therapy Market Challenges

2.3.4 Small Molecule Inhibitors for Cancer Therapy Market Restraints

### **3 COMPETITION LANDSCAPE BY KEY PLAYERS**

3.1 Global Top Small Molecule Inhibitors for Cancer Therapy Players by Revenue

3.1.1 Global Top Small Molecule Inhibitors for Cancer Therapy Players by Revenue (2018-2023)

3.1.2 Global Small Molecule Inhibitors for Cancer Therapy Revenue Market Share by Players (2018-2023)

3.2 Global Small Molecule Inhibitors for Cancer Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Small Molecule Inhibitors for Cancer Therapy Revenue

3.4 Global Small Molecule Inhibitors for Cancer Therapy Market Concentration Ratio

3.4.1 Global Small Molecule Inhibitors for Cancer Therapy Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Small Molecule Inhibitors for Cancer Therapy Revenue in 2022

3.5 Small Molecule Inhibitors for Cancer Therapy Key Players Head office and Area Served

3.6 Key Players Small Molecule Inhibitors for Cancer Therapy Product Solution and Service

3.7 Date of Enter into Small Molecule Inhibitors for Cancer Therapy Market

3.8 Mergers & Acquisitions, Expansion Plans

### **4 SMALL MOLECULE INHIBITORS FOR CANCER THERAPY BREAKDOWN DATA BY TYPE**

4.1 Global Small Molecule Inhibitors for Cancer Therapy Historic Market Size by Type (2018-2023)

4.2 Global Small Molecule Inhibitors for Cancer Therapy Forecasted Market Size by Type (2024-2029)

### **5 SMALL MOLECULE INHIBITORS FOR CANCER THERAPY BREAKDOWN DATA BY APPLICATION**

5.1 Global Small Molecule Inhibitors for Cancer Therapy Historic Market Size by Application (2018-2023)

5.2 Global Small Molecule Inhibitors for Cancer Therapy Forecasted Market Size by Application (2024-2029)

## **6 NORTH AMERICA**

6.1 North America Small Molecule Inhibitors for Cancer Therapy Market Size (2018-2029)

6.2 North America Small Molecule Inhibitors for Cancer Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2018-2023)

6.4 North America Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

## **7 EUROPE**

7.1 Europe Small Molecule Inhibitors for Cancer Therapy Market Size (2018-2029)

7.2 Europe Small Molecule Inhibitors for Cancer Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2018-2023)

7.4 Europe Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

## **8 ASIA-PACIFIC**

8.1 Asia-Pacific Small Molecule Inhibitors for Cancer Therapy Market Size (2018-2029)

8.2 Asia-Pacific Small Molecule Inhibitors for Cancer Therapy Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Small Molecule Inhibitors for Cancer Therapy Market Size by Region (2018-2023)



8.4 Asia-Pacific Small Molecule Inhibitors for Cancer Therapy Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

## **9 LATIN AMERICA**

9.1 Latin America Small Molecule Inhibitors for Cancer Therapy Market Size (2018-2029)

9.2 Latin America Small Molecule Inhibitors for Cancer Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2018-2023)

9.4 Latin America Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

## **10 MIDDLE EAST & AFRICA**

10.1 Middle East & Africa Small Molecule Inhibitors for Cancer Therapy Market Size (2018-2029)

10.2 Middle East & Africa Small Molecule Inhibitors for Cancer Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2018-2023)

10.4 Middle East & Africa Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

## **11 KEY PLAYERS PROFILES**

11.1 Bayer

- 11.1.1 Bayer Company Detail
- 11.1.2 Bayer Business Overview
- 11.1.3 Bayer Small Molecule Inhibitors for Cancer Therapy Introduction
- 11.1.4 Bayer Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023)
- 11.1.5 Bayer Recent Development
- 11.2 Eisai
  - 11.2.1 Eisai Company Detail
  - 11.2.2 Eisai Business Overview
  - 11.2.3 Eisai Small Molecule Inhibitors for Cancer Therapy Introduction
  - 11.2.4 Eisai Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023)
  - 11.2.5 Eisai Recent Development
- 11.3 Zelgen
  - 11.3.1 Zelgen Company Detail
  - 11.3.2 Zelgen Business Overview
  - 11.3.3 Zelgen Small Molecule Inhibitors for Cancer Therapy Introduction
  - 11.3.4 Zelgen Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023)
  - 11.3.5 Zelgen Recent Development
- 11.4 Cipla
  - 11.4.1 Cipla Company Detail
  - 11.4.2 Cipla Business Overview
  - 11.4.3 Cipla Small Molecule Inhibitors for Cancer Therapy Introduction
  - 11.4.4 Cipla Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023)
  - 11.4.5 Cipla Recent Development
- 11.5 Natco Pharma
  - 11.5.1 Natco Pharma Company Detail
  - 11.5.2 Natco Pharma Business Overview
  - 11.5.3 Natco Pharma Small Molecule Inhibitors for Cancer Therapy Introduction
  - 11.5.4 Natco Pharma Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023)
  - 11.5.5 Natco Pharma Recent Development
- 11.6 AstraZeneca
  - 11.6.1 AstraZeneca Company Detail
  - 11.6.2 AstraZeneca Business Overview
  - 11.6.3 AstraZeneca Small Molecule Inhibitors for Cancer Therapy Introduction
  - 11.6.4 AstraZeneca Revenue in Small Molecule Inhibitors for Cancer Therapy

## Business (2018-2023)

11.6.5 AstraZeneca Recent Development

## 11.7 Novartis

11.7.1 Novartis Company Detail

11.7.2 Novartis Business Overview

11.7.3 Novartis Small Molecule Inhibitors for Cancer Therapy Introduction

11.7.4 Novartis Revenue in Small Molecule Inhibitors for Cancer Therapy Business

## (2018-2023)

11.7.5 Novartis Recent Development

## 11.8 Roche

11.8.1 Roche Company Detail

11.8.2 Roche Business Overview

11.8.3 Roche Small Molecule Inhibitors for Cancer Therapy Introduction

11.8.4 Roche Revenue in Small Molecule Inhibitors for Cancer Therapy Business

## (2018-2023)

11.8.5 Roche Recent Development

## 11.9 Bristol-Myers Squibb

11.9.1 Bristol-Myers Squibb Company Detail

11.9.2 Bristol-Myers Squibb Business Overview

11.9.3 Bristol-Myers Squibb Small Molecule Inhibitors for Cancer Therapy Introduction

11.9.4 Bristol-Myers Squibb Revenue in Small Molecule Inhibitors for Cancer Therapy

## Business (2018-2023)

11.9.5 Bristol-Myers Squibb Recent Development

## 11.10 Pfizer

11.10.1 Pfizer Company Detail

11.10.2 Pfizer Business Overview

11.10.3 Pfizer Small Molecule Inhibitors for Cancer Therapy Introduction

11.10.4 Pfizer Revenue in Small Molecule Inhibitors for Cancer Therapy Business

## (2018-2023)

11.10.5 Pfizer Recent Development

## 11.11 BEACON Pharma

11.11.1 BEACON Pharma Company Detail

11.11.2 BEACON Pharma Business Overview

11.11.3 BEACON Pharma Small Molecule Inhibitors for Cancer Therapy Introduction

11.11.4 BEACON Pharma Revenue in Small Molecule Inhibitors for Cancer Therapy

## Business (2018-2023)

11.11.5 BEACON Pharma Recent Development

## 11.12 Jiangxi Shanxiang

11.12.1 Jiangxi Shanxiang Company Detail

- 11.12.2 Jiangxi Shanxiang Business Overview
- 11.12.3 Jiangxi Shanxiang Small Molecule Inhibitors for Cancer Therapy Introduction
- 11.12.4 Jiangxi Shanxiang Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023)
- 11.12.5 Jiangxi Shanxiang Recent Development
- 11.13 Yao Pharma
  - 11.13.1 Yao Pharma Company Detail
  - 11.13.2 Yao Pharma Business Overview
  - 11.13.3 Yao Pharma Small Molecule Inhibitors for Cancer Therapy Introduction
  - 11.13.4 Yao Pharma Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023)
  - 11.13.5 Yao Pharma Recent Development
- 11.14 CSPC
  - 11.14.1 CSPC Company Detail
  - 11.14.2 CSPC Business Overview
  - 11.14.3 CSPC Small Molecule Inhibitors for Cancer Therapy Introduction
  - 11.14.4 CSPC Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023)
  - 11.14.5 CSPC Recent Development
- 11.15 CHIATAI Tianqing
  - 11.15.1 CHIATAI Tianqing Company Detail
  - 11.15.2 CHIATAI Tianqing Business Overview
  - 11.15.3 CHIATAI Tianqing Small Molecule Inhibitors for Cancer Therapy Introduction
  - 11.15.4 CHIATAI Tianqing Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023)
  - 11.15.5 CHIATAI Tianqing Recent Development
- 11.16 Simcere
  - 11.16.1 Simcere Company Detail
  - 11.16.2 Simcere Business Overview
  - 11.16.3 Simcere Small Molecule Inhibitors for Cancer Therapy Introduction
  - 11.16.4 Simcere Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023)
  - 11.16.5 Simcere Recent Development

## **12 ANALYST'S VIEWPOINTS/CONCLUSIONS**

## **13 APPENDIX**

## 13.1 Research Methodology

### 13.1.1 Methodology/Research Approach

### 13.1.2 Data Source

## 13.2 Disclaimer

## 13.3 Author Details

## List Of Tables

### LIST OF TABLES

- Table 1. Global Small Molecule Inhibitors for Cancer Therapy Market Size Growth Rate by Type (US\$ Million): 2018 VS 2022 VS 2029
- Table 2. Key Players of Sorafenib
- Table 3. Key Players of Lenvatinib
- Table 4. Key Players of Regorafenib
- Table 5. Key Players of Osimertinib
- Table 6. Key Players of Anlotinib
- Table 7. Key Players of Alectinib
- Table 8. Key Players of Other
- Table 9. Global Small Molecule Inhibitors for Cancer Therapy Market Size Growth by Application (US\$ Million): 2018 VS 2022 VS 2029
- Table 10. Global Small Molecule Inhibitors for Cancer Therapy Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029
- Table 11. Global Small Molecule Inhibitors for Cancer Therapy Market Size by Region (2018-2023) & (US\$ Million)
- Table 12. Global Small Molecule Inhibitors for Cancer Therapy Market Share by Region (2018-2023)
- Table 13. Global Small Molecule Inhibitors for Cancer Therapy Forecasted Market Size by Region (2024-2029) & (US\$ Million)
- Table 14. Global Small Molecule Inhibitors for Cancer Therapy Market Share by Region (2024-2029)
- Table 15. Small Molecule Inhibitors for Cancer Therapy Market Trends
- Table 16. Small Molecule Inhibitors for Cancer Therapy Market Drivers
- Table 17. Small Molecule Inhibitors for Cancer Therapy Market Challenges
- Table 18. Small Molecule Inhibitors for Cancer Therapy Market Restraints
- Table 19. Global Small Molecule Inhibitors for Cancer Therapy Revenue by Players (2018-2023) & (US\$ Million)
- Table 20. Global Small Molecule Inhibitors for Cancer Therapy Market Share by Players (2018-2023)
- Table 21. Global Top Small Molecule Inhibitors for Cancer Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Small Molecule Inhibitors for Cancer Therapy as of 2022)
- Table 22. Ranking of Global Top Small Molecule Inhibitors for Cancer Therapy Companies by Revenue (US\$ Million) in 2022
- Table 23. Global 5 Largest Players Market Share by Small Molecule Inhibitors for

Cancer Therapy Revenue (CR5 and HHI) & (2018-2023)

Table 24. Key Players Headquarters and Area Served

Table 25. Key Players Small Molecule Inhibitors for Cancer Therapy Product Solution and Service

Table 26. Date of Enter into Small Molecule Inhibitors for Cancer Therapy Market

Table 27. Mergers & Acquisitions, Expansion Plans

Table 28. Global Small Molecule Inhibitors for Cancer Therapy Market Size by Type (2018-2023) & (US\$ Million)

Table 29. Global Small Molecule Inhibitors for Cancer Therapy Revenue Market Share by Type (2018-2023)

Table 30. Global Small Molecule Inhibitors for Cancer Therapy Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 31. Global Small Molecule Inhibitors for Cancer Therapy Revenue Market Share by Type (2024-2029)

Table 32. Global Small Molecule Inhibitors for Cancer Therapy Market Size by Application (2018-2023) & (US\$ Million)

Table 33. Global Small Molecule Inhibitors for Cancer Therapy Revenue Market Share by Application (2018-2023)

Table 34. Global Small Molecule Inhibitors for Cancer Therapy Forecasted Market Size by Application (2024-2029) & (US\$ Million)

Table 35. Global Small Molecule Inhibitors for Cancer Therapy Revenue Market Share by Application (2024-2029)

Table 36. North America Small Molecule Inhibitors for Cancer Therapy Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 37. North America Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2018-2023) & (US\$ Million)

Table 38. North America Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2024-2029) & (US\$ Million)

Table 39. Europe Small Molecule Inhibitors for Cancer Therapy Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 40. Europe Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2018-2023) & (US\$ Million)

Table 41. Europe Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2024-2029) & (US\$ Million)

Table 42. Asia-Pacific Small Molecule Inhibitors for Cancer Therapy Market Size Growth Rate by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 43. Asia-Pacific Small Molecule Inhibitors for Cancer Therapy Market Size by Region (2018-2023) & (US\$ Million)

Table 44. Asia-Pacific Small Molecule Inhibitors for Cancer Therapy Market Size by



Region (2024-2029) & (US\$ Million)

Table 45. Latin America Small Molecule Inhibitors for Cancer Therapy Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 46. Latin America Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2018-2023) & (US\$ Million)

Table 47. Latin America Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2024-2029) & (US\$ Million)

Table 48. Middle East & Africa Small Molecule Inhibitors for Cancer Therapy Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 49. Middle East & Africa Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2018-2023) & (US\$ Million)

Table 50. Middle East & Africa Small Molecule Inhibitors for Cancer Therapy Market Size by Country (2024-2029) & (US\$ Million)

Table 51. Bayer Company Detail

Table 52. Bayer Business Overview

Table 53. Bayer Small Molecule Inhibitors for Cancer Therapy Product

Table 54. Bayer Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023) & (US\$ Million)

Table 55. Bayer Recent Development

Table 56. Eisai Company Detail

Table 57. Eisai Business Overview

Table 58. Eisai Small Molecule Inhibitors for Cancer Therapy Product

Table 59. Eisai Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023) & (US\$ Million)

Table 60. Eisai Recent Development

Table 61. Zelgen Company Detail

Table 62. Zelgen Business Overview

Table 63. Zelgen Small Molecule Inhibitors for Cancer Therapy Product

Table 64. Zelgen Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023) & (US\$ Million)

Table 65. Zelgen Recent Development

Table 66. Cipla Company Detail

Table 67. Cipla Business Overview

Table 68. Cipla Small Molecule Inhibitors for Cancer Therapy Product

Table 69. Cipla Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023) & (US\$ Million)

Table 70. Cipla Recent Development

Table 71. Natco Pharma Company Detail

Table 72. Natco Pharma Business Overview



Table 73. Natco Pharma Small Molecule Inhibitors for Cancer Therapy Product

Table 74. Natco Pharma Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023) & (US\$ Million)

Table 75. Natco Pharma Recent Development

Table 76. AstraZeneca Company Detail

Table 77. AstraZeneca Business Overview

Table 78. AstraZeneca Small Molecule Inhibitors for Cancer Therapy Product

Table 79. AstraZeneca Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023) & (US\$ Million)

Table 80. AstraZeneca Recent Development

Table 81. Novartis Company Detail

Table 82. Novartis Business Overview

Table 83. Novartis Small Molecule Inhibitors for Cancer Therapy Product

Table 84. Novartis Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023) & (US\$ Million)

Table 85. Novartis Recent Development

Table 86. Roche Company Detail

Table 87. Roche Business Overview

Table 88. Roche Small Molecule Inhibitors for Cancer Therapy Product

Table 89. Roche Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023) & (US\$ Million)

Table 90. Roche Recent Development

Table 91. Bristol-Myers Squibb Company Detail

Table 92. Bristol-Myers Squibb Business Overview

Table 93. Bristol-Myers Squibb Small Molecule Inhibitors for Cancer Therapy Product

Table 94. Bristol-Myers Squibb Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023) & (US\$ Million)

Table 95. Bristol-Myers Squibb Recent Development

Table 96. Pfizer Company Detail

Table 97. Pfizer Business Overview

Table 98. Pfizer Small Molecule Inhibitors for Cancer Therapy Product

Table 99. Pfizer Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023) & (US\$ Million)

Table 100. Pfizer Recent Development

Table 101. BEACON Pharma Company Detail

Table 102. BEACON Pharma Business Overview

Table 103. BEACON Pharma Small Molecule Inhibitors for Cancer Therapy Product

Table 104. BEACON Pharma Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023) & (US\$ Million)

Table 105. BEACON Pharma Recent Development

Table 106. Jiangxi Shanxiang Company Detail

Table 107. Jiangxi Shanxiang Business Overview

Table 108. Jiangxi Shanxiang Small Molecule Inhibitors for Cancer Therapy Product

Table 109. Jiangxi Shanxiang Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023) & (US\$ Million)

Table 110. Jiangxi Shanxiang Recent Development

Table 111. Yao Pharma Company Detail

Table 112. Yao Pharma Business Overview

Table 113. Yao Pharma Small Molecule Inhibitors for Cancer Therapy Product

Table 114. Yao Pharma Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023) & (US\$ Million)

Table 115. Yao Pharma Recent Development

Table 116. CSPC Company Detail

Table 117. CSPC Business Overview

Table 118. CSPC Small Molecule Inhibitors for Cancer Therapy Product

Table 119. CSPC Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023) & (US\$ Million)

Table 120. CSPC Recent Development

Table 121. CHIATAI Tianqing Company Detail

Table 122. CHIATAI Tianqing Business Overview

Table 123. CHIATAI Tianqing Small Molecule Inhibitors for Cancer Therapy Product

Table 124. CHIATAI Tianqing Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023) & (US\$ Million)

Table 125. CHIATAI Tianqing Recent Development

Table 126. Simcere Company Detail

Table 127. Simcere Business Overview

Table 128. Simcere Small Molecule Inhibitors for Cancer Therapy Product

Table 129. Simcere Revenue in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023) & (US\$ Million)

Table 130. Simcere Recent Development

Table 131. Research Programs/Design for This Report

Table 132. Key Data Information from Secondary Sources

Table 133. Key Data Information from Primary Sources

## List Of Figures

### LIST OF FIGURES

Figure 1. Global Small Molecule Inhibitors for Cancer Therapy Market Size Comparison by Type (2023-2029) & (US\$ Million)

Figure 2. Global Small Molecule Inhibitors for Cancer Therapy Market Share by Type: 2022 VS 2029

Figure 3. Sorafenib Features

Figure 4. Lenvatinib Features

Figure 5. Regorafenib Features

Figure 6. Osimertinib Features

Figure 7. Anlotinib Features

Figure 8. Alectinib Features

Figure 9. Other Features

Figure 10. Global Small Molecule Inhibitors for Cancer Therapy Market Size Comparison by Application (2023-2029) & (US\$ Million)

Figure 11. Global Small Molecule Inhibitors for Cancer Therapy Market Share by Application: 2022 VS 2029

Figure 12. Hospital Case Studies

Figure 13. Clinic Case Studies

Figure 14. Other Case Studies

Figure 15. Small Molecule Inhibitors for Cancer Therapy Report Years Considered

Figure 16. Global Small Molecule Inhibitors for Cancer Therapy Market Size (US\$ Million), Year-over-Year: 2018-2029

Figure 17. Global Small Molecule Inhibitors for Cancer Therapy Market Size, (US\$ Million), 2018 VS 2022 VS 2029

Figure 18. Global Small Molecule Inhibitors for Cancer Therapy Market Share by Region: 2022 VS 2029

Figure 19. Global Small Molecule Inhibitors for Cancer Therapy Market Share by Players in 2022

Figure 20. Global Top Small Molecule Inhibitors for Cancer Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Small Molecule Inhibitors for Cancer Therapy as of 2022)

Figure 21. The Top 10 and 5 Players Market Share by Small Molecule Inhibitors for Cancer Therapy Revenue in 2022

Figure 22. North America Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 23. North America Small Molecule Inhibitors for Cancer Therapy Market Share

by Country (2018-2029)

Figure 24. United States Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 25. Canada Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 26. Europe Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 27. Europe Small Molecule Inhibitors for Cancer Therapy Market Share by Country (2018-2029)

Figure 28. Germany Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 29. France Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 30. U.K. Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 31. Italy Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 32. Russia Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 33. Nordic Countries Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 34. Asia-Pacific Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 35. Asia-Pacific Small Molecule Inhibitors for Cancer Therapy Market Share by Region (2018-2029)

Figure 36. China Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 37. Japan Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 38. South Korea Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 39. Southeast Asia Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 40. India Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 41. Australia Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 42. Latin America Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 43. Latin America Small Molecule Inhibitors for Cancer Therapy Market Share by Country (2018-2029)

Figure 44. Mexico Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 45. Brazil Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 46. Middle East & Africa Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 47. Middle East & Africa Small Molecule Inhibitors for Cancer Therapy Market Share by Country (2018-2029)

Figure 48. Turkey Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 49. Saudi Arabia Small Molecule Inhibitors for Cancer Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 50. Bayer Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023)

Figure 51. Eisai Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023)

Figure 52. Zelgen Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023)

Figure 53. Cipla Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023)

Figure 54. Natco Pharma Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023)

Figure 55. AstraZeneca Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023)

Figure 56. Novartis Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023)

Figure 57. Roche Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023)

Figure 58. Bristol-Myers Squibb Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023)

Figure 59. Pfizer Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023)

Figure 60. BEACON Pharma Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023)

Figure 61. Jiangxi Shanxiang Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023)

Figure 62. Yao Pharma Revenue Growth Rate in Small Molecule Inhibitors for Cancer

Therapy Business (2018-2023)

Figure 63. CSPC Revenue Growth Rate in Small Molecule Inhibitors for Cancer

Therapy Business (2018-2023)

Figure 64. CHIATAI Tianqing Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023)

Figure 65. Simcere Revenue Growth Rate in Small Molecule Inhibitors for Cancer Therapy Business (2018-2023)

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

## I would like to order

Product name: Global Small Molecule Inhibitors for Cancer Therapy Market Research Report 2023

Product link: <https://marketpublishers.com/r/G98861FDC1E3EN.html>

Price: US\$ 2,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G98861FDC1E3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970